We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- View the Talks
-
1. Genetics and management of inherited cancer predisposition 1
- Prof. Joshua Schiffman
-
2. Genetics and management of inherited cancer predisposition 2
- Prof. Joshua Schiffman
-
3. The cytogenetics of childhood acute leukemia
- Dr. Susana C. Raimondi
-
4. Chromosome translocations and cancer
- Prof. Felix Mitelman
-
5. Acute myeloid leukemia: genetics, prognosis and treatments
- Prof. Stephen Nimer
-
6. Genetic abnormalities in acute lymphoblastic leukemia
- Prof. Ching Hon Pui
-
7. Molecular genetics of non-Hodgkin lymphoma
- Prof. Jude Fitzgibbon
-
8. Genetics of breast and ovarian cancer
- Prof. Jeffrey Weitzel
-
9. The genetics and genomics of familial renal carcinoma
- Prof. Eamonn Maher
-
10. Genomics of lung cancer
- Prof. Ramaswamy Govindan
-
11. The genetics of glioblastoma
- Dr. Hai Yan
-
12. Genetics of tumor metastasis 1
- Prof. Robert Weinberg
-
13. Genetics of tumor metastasis 2
- Prof. Robert Weinberg
-
14. CML: genetic paradigm of targeted therapy 1
- Prof. Michael W. Deininger
-
15. CML: genetic paradigm of targeted therapy 2
- Prof. Michael W. Deininger
-
16. The non-coding RNA revolution in the cancer society
- Prof. George Calin
-
17. Role of molecular markers in guiding therapy in cancer
- Prof. Joe Duffy
-
18. Functional cancer genomics
- Prof. Roderick Beijersbergen
-
19. Pharmacogenomics in cancer therapy
- Prof. Sharon Marsh
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Adverse drug reactions US data
- Factors affecting variability to drug response
- The tumour genome can be very different
- What is pharmacogenomics?
- Adverse drug reactions
- Course of treatment alterations
- Predict right medication and right dose
- Oncology pharmacogenomics
- US FDA approved tests (2014)
- Types and sources of genetic variation
- Polymorphism versus mutation
- DNA variation
- Consequences of polymorphisms
- DPYD intron 14 +1 G>A causes exon skipping
- Multiple types of DNA variation in the same gene
- Sources of polymorphism data-resequencing
- Sources of polymorphism data - databases
- Sources of polymorphism data – curated data
- Techniques to measure genetic variation
- Genotyping – sample types
- Genotyping technology
- Cancer pharmacogenomics and drug selection
- Factors affecting individual genome
- Using the cancer genome against itself
- US FDA approved tests (2014) (2)
- HER2 and breast cancer
- Package insert: required test
- Cancer pharmacogenomics and drug toxicity
- Irinotecan (CPT-11) pathway (1)
- UGT1A1 polymorphisms and irinotecan
- Irinotecan pharmacogenomics
- Camptosar
- Irinotecan (CPT-11) pathway (2)
- Cisplatin-induced ototoxicity
- TPMT/COMT predict risk of cisplatin ototoxicity (1)
- TPMT/COMT predict risk of cisplatin ototoxicity (2)
- Cancer pharmacogenomics and drug outcomes
- Tamoxifen pathway
- CYP2D6 (1)
- CYP2D6 (2)
- Outline: summary
- Summary
- Several challenges
- St. Jude’s Children’s Research Hospital tests
- Uses of pharmacogenomics
- Thank you
Topics Covered
- Pharmacogenomics in cancer therapy
- Types and sources of genetic variation
- Adverse drug reactions
- Techniques to measure genetic variation
- Cancer pharmacogenomics and drug selection
- Cancer pharmacogenomics and drug toxicity
- Irinotecan (CPT-11) pathway
- Cancer pharmacogenomics and drug outcomes
- Tamoxifen pathway
- Uses of pharmacogenomics
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Marsh, S. (2015, October 29). Pharmacogenomics in cancer therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/LMUS1181.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Sharon Marsh has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Sharon Marsh
from the University of Alberta
in Edmonton, Canada.
And this lecture
is on Pharmacogenomics
in Cancer Therapy.
0:09
First, we will go through some
background on pharmacogenomics.
Then we'll discuss the types
and sources
of genetic variation.
We will discuss the techniques
used to measure
genetic variation.
And then we will go through
examples of cancer
pharmacogenomics
and drug selection,
drug toxicity and drug outcomes.
And then we will
summarize the lecture.
We will now
discuss the background
to cancer pharmacogenomics.
0:33
As you can see from this slide,
adverse drug reactions
are a significant problem
to the healthcare system.
Adverse drug reactions are
a reaction
to the medication itself,
not the disease
that the medication
is trying to treat.
This can be particularly
problematic in cancer patients
where the therapeutic window
for treatment is very narrow.
Reduction in dosage
or reduction of medication
or removal of medication
can be detrimental
and potentially fatal
if this has to occur
due to an adverse reaction.
1:05
So what are the causes
of individual variability
in drug response?
They are many.
They range from the environment,
concurrent medications, stress,
smoking status, age,
diet and exercise,
metabolic issues
and, of course, genetics.
Although genetics
can play a major role
in drug disposition
and response,
it is by far
not the only explanation
for failure of a medication
or for an adverse drug reaction.
And it needs to be
taken into account
that genetics will never
be able to explain 100 percent
of all of the variability
in drug response.